Aethlon Medical (NASDAQ:AEMD) Earns “Buy” Rating from HC Wainwright

Aethlon Medical (NASDAQ:AEMD)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $7.00 price objective on the medical equipment provider’s stock.

Separately, StockNews.com assumed coverage on shares of Aethlon Medical in a research note on Monday. They issued a “sell” rating for the company.

Aethlon Medical Price Performance

Shares of NASDAQ:AEMD opened at $0.74 on Thursday. The company has a market cap of $10.35 million, a price-to-earnings ratio of -0.26 and a beta of 1.61. The firm has a 50 day simple moving average of $0.56 and a 200 day simple moving average of $0.45. Aethlon Medical has a one year low of $0.24 and a one year high of $1.88.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.